University of Rochester (UR) University Health Service (UHS)

JYNNEOS (Vaccinia Vaccine) Declination Form

Employee's Name (Print)	Employee's UR	ID Number	Lab Name	/ PI / Supervisor
Complete this form in ink (no pencil, no elec	tronic signature). U	Unless <mark>UHS</mark> i	requests the original	for your medical record
maintain the original in your department's f	iles and send or FA	X a copy to V	JHS (see footer).	

Background

CDC's Advisory Committee on Immunization Practices (ACIP) guidance for JYNNEOS Smallpox and Monkeypox Vaccine (Live, Non-replicating vaccinia vaccine), released in 2022 (https://www.cdc.gov/acip-recs/hcp/vaccine-specific/smallpox-mpox.html), recommends vaccination, with booster dose every 10 years for personnel who directly handle 1) cultures or 2) animals contaminated or infected with:

- replication-competent vaccinia virus, or
- recombinant viruses derived from replication-competent vaccinia strains (i.e., those that are capable of causing clinical infection and producing infectious virus in humans).

UR personnel who perform the activities above but do not wish to be vaccinated must submit this declination form prior to performing these activities.

Vaccination is <u>not</u> required for UR personnel performing the following activities, unless a clinician has recommended vaccination. In these cases, those who do not wish to be vaccinated should also submit a declination form.

- For animals previously administered vaccinia virus—personnel changing cages in a biological safety cabinet or entering the room to check on animals housed in negative ventilated racks
- Health care personnel administering JYNNEOS vaccine

Selected references:

- 1. JYNNEOS FDA approval and product insert https://www.fda.gov/vaccines-blood-biologics/jynneos
- 2. Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak United States, May 22-October 21, 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 9;71(49):1555-1559. DOI: 10.15585/mmwr.mm7149a4
- 3. Use of JYNNEOS (Smallpox and Monkeypox Vaccine, live, nonreplicating) for Preexposure Vaccination of Persons at risk for Occupational Exposure to Orthopoxviruses: Recommendations of the ACIP United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Jun 3;71(22):734-742. DOI: 10.15585/mmwr.mm7122e1
- 4. Laboratory-acquired vaccinia virus infection in a recently immunized person--Massachusetts, 2013. MMWR Morb Mortal Wkly Rep. 2015 May 1;64(16):435-8. PMID: 25928468
- 5. Laboratory-acquired vaccinia virus infection--Virginia, 2008. MMWR Morb Mortal Wkly Rep. 2009 Jul 31;58(29):797-800. PMID: 19644439
- 6. Prevention of vaccinia infection in a laboratory worker. Mil Med. 2007 DOI: 10.7205/milmed.172.10.1117
- 7. Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg Infect Dis. 2006 Jan;12(1):134-7. DOI: 10.3201/eid1201.051126

For additional questions or to receive the vaccine free of charge, call UHS at 275-2662.

Vaccinia Vaccine Declination (based on 29 CFR 1910.1030 Appendix A)

I understand that due to my occupational exposure, I may be at risk of acquiring vaccinia virus infection. I have been given the opportunity to be vaccinated with vaccinia vaccine, at no charge to myself. However, I decline vaccinia vaccination at this time. If in the future I continue to have occupational exposure and I want to be vaccinated with vaccinia vaccine, I can receive the vaccine at no charge to me.

rev: 11-20-2024

Employee's Signature	Date	
Employee's Home Address	Employee's Telephone Number	